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Abstract
Frequent gains of chromosome 20q12-13 in ovarian tumors indicate that at least one important
oncogene is found at that locus. One of the genes there is EEF1A2, which maps to 20q13.3 and
encodes protein elongation factor eEF1A2. This review will focus on recent evidence indicating that
EEF1A2 is an important ovarian oncogene and that the protein elongation network can activate
tumorigenesis and inhibit apoptosis.
Genetic alterations are the driving force of oncogenesis
[1]. In the form of individual nucleotide mutations and
small deletions, these changes activate growth-promoting
oncogenes and inactivate tumour-suppressors. On the
larger chromosomal scale, tumours also possess DNA
deletions and amplifications that span hundreds of mil-
lions of nucleotides and dozens of genes. The presence of
common cytogenetic abnormalities in tumours of the
same type implies that these changes are not the simple
consequence of tumour development but rather have a
causal role in oncogenesis. Considerable effort, therefore,
is devoted to characterizing tumour-associated chromo-
somal abnormalities and identifying the critical gene or
genes involved. It is hoped that this will provide new
prognostic markers for cancer and lead to the identifica-
tion of novel therapeutic targets. This review will focus on
20q13, a locus amplified in half of ovarian cancers and
protein elongation factor EEF1A2, an important oncogene
found there.
20q gene amplification and ovarian cancer
The most commonly used techniques to identify tumour-
specific chromosomal changes are Comparative Genomic
Hybridization (CGH) [2] and Fluorescent In Situ Hybrid-
ization (FISH) [3]. Both technologies rely on fluorescence
microscopy to quantify cytogenetic alterations in individ-
ual tumours. FISH uses a DNA probe homologous to a
known chromosomal position to determine the cytoge-
netic status of that locus. The resolution of FISH is high
and is limited only by size of the probe, usually in the 50–
200 kb range. Various FISH protocols can assay 24 or
more different probes simultaneously [4], but typically
only one or two loci are studied. On the other hand, CGH
allows the entire chromosomal content of a tumour to be
compared to normal DNA in a single experiment without
a multitude of mapped probes. CGH has a much lower
resolution than FISH, usually 3–5 Mb. CGH and FISH
studies on human ovarian tumour samples have revealed
common amplifications at 20q, 3q, and 8q [5].
Approximately 50% of ovarian tumours and cell lines
have copy number increases in 20q [6–8]. The 20q ovar-
ian amplicon has yet to be precisely sequenced or
mapped, but is known to include at least part of 20q12
and 20q13. 20q12-13 amplifications in ovarian tumours
are associated with poorer survival and a more aggressive
tumour pathology than those with normal 20q copy
number [8,9]. 20q12-13 amplifications are also found in
a variety of other solid tumours, most notably breast [10]
and colorectal cancer [11].
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The frequent amplification of 20q12-13 in ovarian
tumours argues that at least one of the genes found there
is actively promoting tumorigenesis. As of December
2002, the Genome Database (GDB) of the Human
Genome Organization (HUGO) has identified 132 genes
in 20q12-13 [12]. The protein products of these genes
spans a broad range of enzymatic activities that includes
kinases, phosphatases, phospholipases, ribosomal pro-
teins and protein translation factors. Moreover, the func-
tion of many 20q12-13 genes has yet to be established. It
seems unlikely that all 132 genes are important in ovarian
cancer. One or more 20q12-13 genes could directly pro-
mote tumour growth or two or more genes may cooperate
to drive tumour development.
Four genes mapping to 20q12-13, ZNF217,  PTP1B,
STK15/BTAK, and MYBL2, seem to be likely candidates as
promoters of ovarian tumor development. ZNF217
encodes a putative transcription factor that can cause the
immortalization of human mammary epithelial cells
[13,14]. Increased ZNF217 expression increases telomer-
ase activity and stabilizes telomere length [14], but the
mechanism by which it does so and the genes whose tran-
scription it directly activates have yet to be identified.
PTB1B  encodes a protein tyrosine phosphatase that,
among other substrates, dephosphorylates and activates
the Src kinase[15]. Src is the founding member of a tyro-
sine kinase family that are well-characterized promoters
of oncogenesis [16]. STK15/BTK is a centrosome-associ-
ated protein kinase that controls centrosome distribution
during mitosis [17]. Increased STK15/BTAK expression
can promote the tumorigenicity of multiple mouse and
rodent cell lines and its ectopic expression leads to centro-
somal defects and aneuploidy [17]. MYBL2 is a homo-
logue of the v-myb avian oncogene whose enforced
expression can transform avian and mammalian cell lines
[18]. A plausible case can be made that all of these genes
may contribute in some way to ovarian tumor develop-
ment. However, the actual role that each of these proteins
play in ovarian tumorigenesis have yet to be ascertained.
Protein elongation factor eEF1A2
My lab has focused on attention on another gene in the
20q amplicon, EEF1A2. EEF1A2 maps to 20q13.3 [19]
and encodes protein elongation factor eEF1A2. By con-
vention, EEF1A2 refers to the human gene and eEF1A2
refers to the protein product. eEF1A2 is a protein transla-
tion factor. Protein translation is conceptually divided
into three stages: initiation, elongation, and termination.
Comprehensive reviews of each stage are found elsewhere
[20–22]. Simply, the assembly of ribosomal subunits and
the initiator methionine tRNA at the mRNA's AUG is
termed initiation. The sequential addition of amino acids
to the methionine and the translocation of the ribosome
along the mRNA is described as elongation. At termina-
tion, the ribosomal subunits and the newly formed
polypeptide dissociate from the mRNA. Each stage of pro-
tein translation is controlled by multimeric protein fac-
tors, eIF (eukaryotic Initiation Factor), eEF (eukaryotic
Elongation Factor) and eRF (eukaryotic Release Factor),
that respectively regulate initiation, elongation and termi-
nation.
eEF1A2 is one of two isoforms (eEF1A1 and eEF1A2) of
eukaryotic elongation factor 1 alpha (eEF1A or eEF1α).
Both eEF1A proteins directly bind amino acylated tRNA
and direct its association with the ribosome and mRNA
codon [21]. The two human isoforms share>90%
sequence identity and have essentially the same function
during protein translation. The expression patterns of the
two isoforms are markedly different, however. In humans,
eEF1A1 is expressed ubiquitously whereas eEF1A2 expres-
sion is restricted to the heart, brain, and skeletal muscle
[23]. The functional significance of the tissue-specific
expression pattern of eEF1A2 has yet to be determined.
At first blush, the seemingly banal function of eEF1A2
does not appear to make it a likely candidate as an ovarian
cancer oncogene. Our lab first became interested in
eEF1A2 because of the Wasted mouse (wst/wst). First
described by Shultz and collaborators in 1982 [24],
Wasted is a spontaneous recessive mutation in HRS/J mice
that leads to immuno-deficiency, neural abnormalities
and progressive muscular wasting. Wasted mice die at
approximately 30 days of age [24]. Cells derived from
Wasted mice show higher sensitivity to DNA damage-
induced cell death than controls and their lymphoid
organs are smaller and show dramatically elevated levels
of apoptosis compared to their littermates [25,26]. The
Wasted phenotype results from a deletion of the promoter
and first exon of the mouse Eef1A2 gene, which is the
human  EEF1A2  homologue [27]. The mouse gene
nomenclature differs from that of the human. Since a
homozygous deletion of Eef1A2 leads to increased apop-
tosis in Wasted mice [26], we reasoned that EEF1A2
amplification in ovarian cancers might lead to an inhibi-
tion of apoptosis, a process that could plausibly contrib-
ute to neoplastic progression. Moreover, the mapping of
EEF1A2  to 20q13 [19] provided another rationale for
investigating it as a potential oncogene in ovarian cancer.
EEF1A2, an unusual oncogene
Historically, for a gene to be considered a tumour-pro-
moting oncogene, it should be hyper-activated or hyper-
expressed in primary human cancers and have the capac-
ity to "transform" rodent cells cultured in vitro. Transform-
ing ability means that expression of the gene can cause
fibroblast cells to grow in an anchorage-independent
manner and to form dome-like structures in tissue culture
called foci. This definition of an oncogene is somewhatReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/69
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arbitrary and by no means absolute, but most generally
accepted oncogenes have these properties.
We have found that EEF1A2 is increased in copy number
in about one third of primary ovarian tumors [28].
eEF1A2 mRNA is not detectable in normal ovarian epithe-
lium but about a third of human ovarian tumours have
measurable EEF1A2 mRNA [28]. eEF1A1 expression, on
the other hand, is not detectably changed between normal
and ovarian tumour samples. Importantly, ectopic expres-
sion of wild-type eEF1A2 transforms mouse and rat
fibroblasts and allows them to grow as tumors when
xenografted into mice. When eEF1A2 is expressed in a
human ovarian cell line that does not express eEF1A2, the
eEF1A2-expressing line is more tumorigenic than that of
its parental control [28]. EEF1A2 amplification, increased
mRNA expression and its transforming potential indicate
that eEF1A2 is an important ovarian cancer oncogene. It is
unlikely that EEF1A2  is the only oncogene in the 20q
amplicon important to ovarian cancer. As summarized
above, there are many potential oncogenes there and per-
haps amplification of all of them is necessary for tumour
development. Moreover, it has yet to be demonstrated
whether eEF1A2 can directly promote tumorigenesis in
transgenic mouse models of ovarian cancer, but this is a
research avenue that our lab is actively pursuing.
Protein translation factors as oncogenes
Tatsuka and colleagues were the first to implicate the pro-
tein elongation machinery in cell transformation [29].
They screened a mouse expression library for genes that
would enhance the rate of spontaneous and chemically-
induced transformation of mouse and hamster fibrob-
lasts. One of the genes they identified was Eef1A1, the
mouse homologue of human EEF1A1, which increased
the transforming ability of 3-methylcholanthrene and
ultraviolet light [29]. The first report linking human
EEF1A1 to cancer was work from Paul Fisher's group at
Columbia University, who identified a gene expressed in
primary prostate carcinomas but not in normal prostate
[30]. They named this gene PTI-1 for prostate tumor
inducing gene 1. Expression of PTI-1 in non-tumorigenic
prostate cell lines made these cells tumorigenic in nude
mice. When sequenced, PTI-1 turned out to be a fusion
between a Mycoplasma hyopheumoniae 23S ribosomal RNA
gene and a mutated form of human EEF1A1. This work
raised the possibility that the fusion of a gene from an
infectious agent (Mycoplasma) and a human gene could
have created a novel prostate cancer oncogene. However,
the unusual composition of PTI-1 raised the possibility
that PTI-1 was a laboratory epiphenomenon. PTI-1 has
been detected in other tumour cell lines [31,32] but the
relevance of PTI-1 to prostate and other cancers still
remains an unresolved, albeit intriguing, issue.
eEF1A1 and eEF1A2 are not the only protein translation
factors implicated in cancer. eIF4E, an mRNA cap-binding
involved in protein initiation, transforms NIH 3T3 cells
and allows them to grow as tumors in mice [33]. EIF4E,
the human eIF4E gene, maps to 4q21, a locus amplified in
the vast majority of non-small cell lung cancers [34] and
some breast tumors [35]. Furthermore, abnormally high
eIF4E expression is observed in many solid tumours [36–
39].
eEF1A proteins regulate apoptosis
The elevated apoptosis in the eEF1A2-deficient Wasted
mice [26] is at least consistent with the idea that eEF1A2,
and the related eEF1A1, might be inhibitors of apoptosis.
Consistent with this idea, eEF1A1 was recently cloned in a
screen for genes that protect against apoptosis induced by
IL-3 withdrawal [40]. Furthermore, ectopic rat eEF1A2
expression can protect muscle cells from caspase-3-
induced apoptosis [41]. These results imply that eEF1A1
and eEF1A2 both inhibit apoptosis. Interestingly, a recent
report suggests that the acquisition of cisplatin resistance
in a human head and neck cancer cell line was associated
with increased eEF1A1 expression [42]. Increased expres-
sion of eEF1A1, relative to normal tissue, occurs in
melanomas, tumors of the pancreas, breast, lung, prostate
and colon [42–47]. Given this high tumour-specific
expression of eEF1A1 and eEF1A2, it is tempting to spec-
ulate that their expression might contribute to resistance
to anti-cancer therapy, especially in ovarian cancer. It is
also intriguing to think that the ability of both eEF1A1
and eEF1A2 to enhance cell growth and tumorigenesis
could be related to their ability to inhibit apoptosis.
How does it work?
How might the ectopic expression of an elongation factor
enhance cell growth and inhibit apoptosis? eEF1A pro-
teins could specifically upregulate the production of pro-
teins that activate cell replication and growth such as Ras
or Myc. It is hard to understand, however, how eEF1A2
could upregulate the production of specific proteins. The
coding region of an mRNA is the only place where an
elongation factor interacts with a functional ribosome/
mRNA complex. A protein's mRNA coding region pre-
sumably lacks any information other than that for the
polypeptide's primary amino acid sequence. Thus, it
seems unlikely that proteins with oncogenic potential
could carry some kind of specific information or second-
ary structure in their coding region that would make them
specific candidates for elongation activation in the pres-
ence of high amounts of eEF1A2.
On the other hand, increased eEF1A1 and eEF1A2 expres-
sion may not specifically increase the production of par-
ticular proteins but rather lead to an overall increase in
protein translation. An increase in bulk protein synthesisReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/69
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may enhance cell replication because cell division
requires sufficient protein production to fulfill the meta-
bolic and size requirements of two new daughter cells
[48]. Increasing bulk protein abundance may decrease the
time required to translate the overall mass of proteins nec-
essary for cell division. If this is the case, then it would be
expected that anything increasing protein translation rates
would be predicted to be oncogenic. The reverse is cer-
tainly true, and inhibitors of protein translation are uni-
versally and highly toxic to cells and organisms.
Alternatively, eEF1A proteins may enhance tumorigenesis
independent of the protein translation network. eEF1A
proteins are known to associate with actin and tubulin,
and ectopic eEF1A expression can decrease the length of
actin filaments and tubulin microtubules [49,50]. Per-
haps, the ability of eEF1A to alter cell structure somehow
contributes to a neoplastic phenotype. However, the phys-
iological importance of the association of eEF1A with the
cytoskeleton has yet to be clearly established, so it is
unclear how eEF1A1 and eEF1A2 might control cell
growth though cytoskeletal interaction.
An eEF1A2-centered perspective on ovarian 
cancer
While we have established that the eEF1A2 is genetically
amplified and overexpressed in ovarian tumours and has
oncogenic properties, it has yet to be shown whether
eEF1A2 expression can directly cause ovarian or other can-
cers in animals. Furthermore, we have yet to understand
the mechanism by which eEF1A2 promotes tumorigene-
sis. In the absence of mechanistic insight, there are still
important issues that need addressing with regard to
eEF1A2 and ovarian cancer. Firstly, is EEF1A2  copy
number or eEF1A2 protein expression an ovarian cancer
prognostic factor? Secondly, is eEF1A2 a suitable target for
anticancer therapy? It could be argued that because all
cells require protein synthesis, inhibitors of protein elon-
gation would have substantial cytotoxic effects on normal
tissues. However, rapidly growing tumor tissue may be
more sensitive to decreases in protein synthesis than nor-
mal tissue because of the added burdens of an increased
proliferation rate. A similar relationship has been
exploited in the use of DNA-damaging agents in cancer
treatment. Indeed, Rapamycin, an inhibitor of eIF4E-
dependent protein initiation, is now being tested in breast
cancer [51]. Perhaps, when eEF1A2-inactivating agents are
found, they might have efficacy in ovarian cancer.
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